Table of contents

  1. Front Matter
    Pages i-xiii
  2. Physiology of HDL

    1. Front Matter
      Pages 1-1
    2. Anatol Kontush, Mats Lindahl, Marie Lhomme, Laura Calabresi, M. John Chapman, W. Sean Davidson
      Pages 3-51 Open Access
    3. Vassilis I. Zannis, Panagiotis Fotakis, Georgios Koukos, Dimitris Kardassis, Christian Ehnholm, Matti Jauhiainen et al.
      Pages 53-111 Open Access
    4. Dimitris Kardassis, Anca Gafencu, Vassilis I. Zannis, Alberto Davalos
      Pages 113-179 Open Access
    5. Elda Favari, Angelika Chroni, Uwe J. F. Tietge, Ilaria Zanotti, Joan Carles Escolà-Gil, Franco Bernini
      Pages 181-206 Open Access
    6. Helen Karlsson, Anatol Kontush, Richard W. James
      Pages 207-228 Open Access
  3. Pathology of HDL

    1. Front Matter
      Pages 257-257
    2. Menno Hoekstra, Miranda Van Eck
      Pages 301-336 Open Access
    3. Meliana Riwanto, Lucia Rohrer, Arnold von Eckardstein, Ulf Landmesser
      Pages 337-366 Open Access
  4. Possible Indications and Target Mechanisms of HDL Therapy

    1. Front Matter
      Pages 367-367
    2. Wijtske Annema, Arnold von Eckardstein, Petri T. Kovanen
      Pages 369-403 Open Access
    3. Peter Vollenweider, Arnold von Eckardstein, Christian Widmann
      Pages 405-421 Open Access
    4. Mirjam Schuchardt, Markus Tölle, Markus van der Giet
      Pages 423-453 Open Access
    5. Fabrizio Montecucco, Elda Favari, Giuseppe Danilo Norata, Nicoletta Ronda, Jerzy-Roch Nofer, Nicolas Vuilleumier
      Pages 455-482 Open Access
    6. Angela Pirillo, Alberico Luigi Catapano, Giuseppe Danilo Norata
      Pages 483-508 Open Access
    7. Olivier Meilhac
      Pages 509-526 Open Access

About this book

Introduction

In this Handbook of Experimental Pharmacology on “High Density Lipoproteins – from biological understanding to clinical exploitation” contributing authors (members of COST Action BM0904/HDLnet) summarize in more than 20 chapters our current knowledge on the structure, function, metabolism and regulation of HDL in health and several diseases as well as the status of past and ongoing attempts of therapeutic exploitation.

The book is of interest to researchers in academia and industry focusing on lipoprotein metabolism, cardiovascular diseases and immunology as well as clinical pharmacologists, cardiologists, diabetologists, nephrologists and other clinicians interested in metabolic or inflammatory diseases.

Keywords

HDL animal models atherosclerosis inflammation reverse cholesterol transport risk factors

Editors and affiliations

  • Arnold von Eckardstein
    • 1
  • Dimitris Kardassis
    • 2
  1. 1.University Hospital Zurich Institute of Clinical ChemistryZurichSwitzerland
  2. 2.University of Crete Medical SchoolIraklion, CreteGreece

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-09665-0
  • Copyright Information The Editor(s)(if applicable) and the Author(s) 2015
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-09664-3
  • Online ISBN 978-3-319-09665-0
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • About this book